How to make an oligodendrocyte

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

How to make an oligodendrocyte. / Goldman, Steven A.; Kuypers, Nicholas J.

In: Development, Vol. 142, No. 23, 01.12.2015, p. 3983-3995.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Goldman, SA & Kuypers, NJ 2015, 'How to make an oligodendrocyte', Development, vol. 142, no. 23, pp. 3983-3995. https://doi.org/10.1242/dev.126409

APA

Goldman, S. A., & Kuypers, N. J. (2015). How to make an oligodendrocyte. Development, 142(23), 3983-3995. https://doi.org/10.1242/dev.126409

Vancouver

Goldman SA, Kuypers NJ. How to make an oligodendrocyte. Development. 2015 Dec 1;142(23):3983-3995. https://doi.org/10.1242/dev.126409

Author

Goldman, Steven A. ; Kuypers, Nicholas J. / How to make an oligodendrocyte. In: Development. 2015 ; Vol. 142, No. 23. pp. 3983-3995.

Bibtex

@article{cfd231b472f64eeebe46e495cfb39683,
title = "How to make an oligodendrocyte",
abstract = "Oligodendrocytes produce myelin, an insulating sheath required for the saltatory conduction of electrical impulses along axons. Oligodendrocyte loss results in demyelination, which leads to impaired neurological function in a broad array of diseases ranging from pediatric leukodystrophies and cerebral palsy, to multiple sclerosis and white matter stroke. Accordingly, replacing lost oligodendrocytes, whether by transplanting oligodendrocyte progenitor cells (OPCs) or by mobilizing endogenous progenitors, holds great promise as a therapeutic strategy for the diseases of central white matter. In this Primer, we describe the molecular events regulating oligodendrocyte development and how our understanding of this process has led to the establishment of methods for producing OPCs and oligodendrocytes from embryonic stem cells and induced pluripotent stem cells, as well as directly from somatic cells. In addition, we will discuss the safety of engrafted stem cell-derived OPCs, as well as approaches by which to modulate their differentiation and myelinogenesis in vivo following transplantation.",
author = "Goldman, {Steven A.} and Kuypers, {Nicholas J.}",
note = "{\textcopyright} 2015. Published by The Company of Biologists Ltd.",
year = "2015",
month = dec,
day = "1",
doi = "10.1242/dev.126409",
language = "English",
volume = "142",
pages = "3983--3995",
journal = "Development",
issn = "0950-1991",
publisher = "The Company of Biologists",
number = "23",

}

RIS

TY - JOUR

T1 - How to make an oligodendrocyte

AU - Goldman, Steven A.

AU - Kuypers, Nicholas J.

N1 - © 2015. Published by The Company of Biologists Ltd.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Oligodendrocytes produce myelin, an insulating sheath required for the saltatory conduction of electrical impulses along axons. Oligodendrocyte loss results in demyelination, which leads to impaired neurological function in a broad array of diseases ranging from pediatric leukodystrophies and cerebral palsy, to multiple sclerosis and white matter stroke. Accordingly, replacing lost oligodendrocytes, whether by transplanting oligodendrocyte progenitor cells (OPCs) or by mobilizing endogenous progenitors, holds great promise as a therapeutic strategy for the diseases of central white matter. In this Primer, we describe the molecular events regulating oligodendrocyte development and how our understanding of this process has led to the establishment of methods for producing OPCs and oligodendrocytes from embryonic stem cells and induced pluripotent stem cells, as well as directly from somatic cells. In addition, we will discuss the safety of engrafted stem cell-derived OPCs, as well as approaches by which to modulate their differentiation and myelinogenesis in vivo following transplantation.

AB - Oligodendrocytes produce myelin, an insulating sheath required for the saltatory conduction of electrical impulses along axons. Oligodendrocyte loss results in demyelination, which leads to impaired neurological function in a broad array of diseases ranging from pediatric leukodystrophies and cerebral palsy, to multiple sclerosis and white matter stroke. Accordingly, replacing lost oligodendrocytes, whether by transplanting oligodendrocyte progenitor cells (OPCs) or by mobilizing endogenous progenitors, holds great promise as a therapeutic strategy for the diseases of central white matter. In this Primer, we describe the molecular events regulating oligodendrocyte development and how our understanding of this process has led to the establishment of methods for producing OPCs and oligodendrocytes from embryonic stem cells and induced pluripotent stem cells, as well as directly from somatic cells. In addition, we will discuss the safety of engrafted stem cell-derived OPCs, as well as approaches by which to modulate their differentiation and myelinogenesis in vivo following transplantation.

U2 - 10.1242/dev.126409

DO - 10.1242/dev.126409

M3 - Journal article

C2 - 26628089

VL - 142

SP - 3983

EP - 3995

JO - Development

JF - Development

SN - 0950-1991

IS - 23

ER -

ID: 152955602